

From the March 23, 2018
 Florida Pharmaceutical & Therapeutics Committee Meeting
 (Changes Effective April 1, 2018)

ACNE AGENTS, TOPICAL	PDL Status Before Meeting	PDL Status After Meeting	Comments
RETIN-A MICRO 0.06% PUMP (TOPICAL)	NA	Non-PDL	
ANGIOTENSIN MODULATORS			
CAPTOPRIL (ORAL)	PDL	Non-PDL	
ANTHELMINTICS			
ALBENZA (ORAL)	NR	PDL	
BILTRICIDE (ORAL)	NR	PDL	
EMVERM (ORAL)	NR	Non-PDL	
IVERMECTIN (ORAL)	NR	PDL	
STROMEKTOL (ORAL)	NR	Non-PDL	
ANTIDIARRHEALS			
MOTOFEN (ORAL)	NA	Non-PDL	
ANTIEMETIC/ANTIVERTIGO AGENTS			
CINVANTI (INTRAVEN)	NA	PDL	
VARUBI (INTRAVEN)	NA	Non-PDL	
ANTIFUNGALS, INJECTABLE			
ABELCET (INTRAVEN)	PDL	Non-PDL	
ANTIPROTOZOALS			
IMPAVIDO (ORAL)	NA	Non-PDL	
COUGH AND COLD, NARCOTIC			
HYDROCODONE/HOMATROPINE TABLET (ORAL)	PDL	Non-PDL	
TUZISTRA XR SUSPENSION (ORAL)	NA	Non-PDL	
CYTOKINE AND CAM ANTAGONISTS			
ENBREL CARTRIDGE (SUBCUTANE.)	NA	PDL	
GLUCOCORTICIDS, INHALED			
FLOVENT DISKUS (INHALATION)	PDL	Non-PDL	
QVAR REDHALER (INHALATION)	NA	Non-PDL	
TRELEGY ELLIPTA (INHALATION)	NA	Non-PDL	
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS			
BYDUREON BCISE (SUBCUTANE.)	NA	Non-PDL	
OZEMPIC (SUBCUTANE.)	NA	Non-PDL	
QTERN (ORAL)	NA	Non-PDL	
HYPOGLYCEMICS, MEGLITINIDES			
NATEGLINIDE (ORAL)	PDL	Non-PDL	
IDIOPATHIC PULMONARY FIBROSIS			
OFEV (ORAL)	Non-PDL	PDL	Clinical PA
IMMUNOMODULATORS, ASTHMA			
FASENRA (SUB-Q)	NA	Non-PDL	
IMMUNOMODULATORS, ATOPIC DERMATITIS			
EUCRISA (TOPICAL)	Non-PDL	PDL	

METHOTREXATE			
XATMEP SOLUTION (ORAL)	NA	Non-PDL	
OPHTHALMICS, GLAUCOMA AGENTS			
VYZULTA (OPHTHALMIC)	NA	Non-PDL	
PAH AGENTS, ORAL AND INHALED			
TRACLEER SUSPENSION (ORAL)	NA	Non-PDL	
PHOSPHATE BINDERS			
CALCIUM ACETATE TABLET (ORAL)	PDL	Non-PDL	
STEROIDS, TOPICAL LOW			
DERMA-SMOOTHIE-FS (TOPICAL)	Non-PDL	PDL	
FLUOCINOLONE 0.01% OIL (TOPICAL)	PDL	Non-PDL	
TETRACYCLINES			
TARGADOX (ORAL)	NA	Non-PDL	
XIMINO (ORAL)	NA	Non-PDL	
VAGINAL ESTROGEN PREPARATIONS			
INTRAROSA (VAGINAL)	NA	Non-PDL	

NA = Not Applicable (for new products)

NR = Not Previously Reviewed